UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Learn which dividend ETFs are inexpensive and still offer reliable income. Compare fee structures and performance to choose cost-conscious options.
20,642 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A private Philadelphia moment between Beyoncé and Jay-Z offers more than star power. This piece breaks down the finan...
On a day when the S&P 500 slipped, KLA Corporation stood out. An aggressive price-target upgrade and a scheduled stoc...
A hypothetical Fed Chair Warsh could steer policy in ways that alter consumer demand and corporate borrowing costs. T...
Investors want a clear compass for Alphabet stock in the next five years. This article breaks down the growth drivers...
A Fulton Financial director sold shares after the stock surged about 26%. This article breaks down what insider sales...
Nike has steadied after a challenging period, yet investors should brace for the real test: translating a stabilized ...
An equal-weight large-cap ETF is gaining attention as a retirement-friendly alternative to cap-weighted funds. Here’s...
Robinhood just announced a substantial $1.5 billion buyback. In this analysis, we weigh the potential benefits agains...
Alibaba's latest earnings mix puts cloud momentum in the spotlight while profitability falters. This article untangle...
AMLP offers a steady, roughly 7% yield from energy infrastructure. This article explains why most retirees overlook A...
Regulators pause the Union Pacific Norfolk Southern megamerger review, injecting regulatory risk for Norfolk Southern...